Last reviewed · How we verify

ARCT-810 — Competitive Intelligence Brief

ARCT-810 (ARCT-810) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Self-amplifying RNA (saRNA) therapeutic. Area: Oncology.

phase 2 Self-amplifying RNA (saRNA) therapeutic Arginase-1 (ARG1) Oncology Biologic Live · refreshed every 30 min

Target snapshot

ARCT-810 (ARCT-810) — Arcturus Therapeutics, Inc.. ARCT-810 is a self-amplifying RNA (saRNA) therapeutic that encodes a secreted form of arginase-1 to modulate immune responses in cancer.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ARCT-810 TARGET ARCT-810 Arcturus Therapeutics, Inc. phase 2 Self-amplifying RNA (saRNA) therapeutic Arginase-1 (ARG1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Self-amplifying RNA (saRNA) therapeutic class)

  1. Arcturus Therapeutics, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ARCT-810 — Competitive Intelligence Brief. https://druglandscape.com/ci/arct-810. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: